Current application and resistance mechanisms of sintilimab combined with bevacizumab in advanced hepatocellular carcinoma
- VernacularTitle:信迪利单抗联合贝伐珠单抗在晚期肝细胞癌中的应用现状与耐药机制
- Author:
Linglong LIU
1
;
Yan LIU
2
Author Information
- Publication Type:Review
- Keywords: Carcinoma， Hepatocellular; Sintilimab; Bevacizumab; Drug Resistance， Neoplasm; Biomarkers， Tumor
- From: Journal of Clinical Hepatology 2026;42(7):1698-1703
- CountryChina
- Language:Chinese
- Abstract: Hepatocellular carcinoma （HCC） imposes a significant global disease burden， and the development of HCC is closely associated with an immunosuppressive tumor microenvironment. Systemic therapy for advanced HCC has entered the era of immune combination therapy. The ORIENT-32 study has established the regimen of sintilimab combined with bevacizumab as the first-line therapy， and multiple real-world studies have confirmed its clinical value. Overcoming drug resistance remains a major challenge during the application of various combination regimens of targeted therapy and immunotherapy， including this particular regimen. Current research focus is gradually shifting toward deciphering its clinical phenotypes and molecular mechanisms， while promoting the clinical translation of biomarkers from static prediction to dynamic monitoring. In the future， overcoming drug resistance， optimizing combination strategies， and achieving precise individualized treatment are key to enhancing the survival benefit of patients. This article systematically evaluates the efficacy and safety of the sintilimab+bevacizumab regimen in a real-world setting， preliminarily discusses its drug resistance mechanism， and reviews the research advances in the biomarkers for predicting treatment response and guiding drug resistance overcoming， in order to provide a basis for optimizing the precise treatment strategies for advanced HCC.
